# A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

> **NCT00363714** · PHASE1,PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 26 (actual)

## Conditions studied

- Age-Related Macular Degeneration
- Choroidal Neovascularization

## Interventions

- **DRUG:** AGN211745
- **DRUG:** AGN211745
- **DRUG:** AGN211745
- **DRUG:** AGN211745
- **DRUG:** AGN211745
- **DRUG:** AGN211745

## Key facts

- **NCT ID:** NCT00363714
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2008-08-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00363714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00363714, "A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00363714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*